CVS Health Corporation

Valuation Analysis

About the Company

CVS Health Corporation en bref

CVS Health Corporation (CVS) is currently trading at 85,72 € with a market capitalization of 109,4 Md €. The trailing P/E ratio stands at 43.13x, with a forward P/E of 11.73x. The 52-week range spans from 51,00 € to 89,59 €; the current price is 4.3% below the yearly high. Year-over-year revenue growth stands at +6.1%. The net profit margin stands at 0.72%.

💰 Dividende

CVS Health Corporation pays an annual dividend of 2,32 € per share, representing a yield of 2.71%. The payout ratio stands at 116.67%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

26 analystes évaluent CVS Health Corporation (CVS) au consensus : Achat Fort. L'objectif de cours moyen est de 91,54 €, soit un potentiel de +6.78% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 68,87 € à 122,05 €.

CVS Health Corporation : la thèse d'investissement en détail

CVS Health Corporation (CVS) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Earnings growth of 63.1% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

Le scénario baissier

With a net margin of just 0.72%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.28, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 11.73x is meaningfully below the trailing 43.13x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 90% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy CVS Health Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.